Watch this WEBINAR first.
DOWNLOAD THE SLIDES and CHECKLIST
Fill in your NAME and EMAIL to receive the CHECKLIST and SLIDES from the webinar via eMail!
What is Hyperthermia Treatment?
Hyperthermia means simply that the body temperature has raised higher than normal levels. Hyperthermia can also refer to heat treatment or hyperthemia treatment in which heat is used in carefully controlled medical procedures.
Hyperthermia therapy or thermal therapy is a type of cancer treatment in which cancer cells are exposed to elevated temperatures. This has several effects including:
Hyperthermia Treatment in a Far Infrared Sauna Dome
The TRULY HEAL Far Infrared Sauna Dome is great if you would like to have a hyperthermia treatment in the comfort of your own home. Its portable and sets up in under 15 minutes. Consider it your own personal immune booster and deep tissue detoxifier. As soon as you realize the effects of this treatment the dome will become the single most important tool in your immune boosting arsenal. This Far Infrared Sauna Dome is equipped with extra powerful True Wave infrared heaters, which are patented for their low EMF technology and sleek design. The added power allows you to reach elevated temperatures in a very short time just as if you were in a clinic.
“If we would stop using fever suppressing medicine we would see a lot more healthy people and our natural way to fight infections would still work.”
Dr. Haller, Germany
Isn’t fever dangerous though?
Whole-body hyperthermia therapy raises the body temperature to a level similar to a fever. It is sometimes referred to as Fever-range Whole-body Hyperthermia. Extremely high body temperatures can be dangerous but carefully controlled and monitored use of hyperthermia where the patient is kept hydrated and their head cooled can boost the immune system.
In case you are scared of fever, temperatures of 102° F/ 38.9°C are considered very common and are extremely healthy. Temperatures of 104°F/ 40°C are self regulating, needing supervision but not necessarily suppression. A fever should never be neglected as they can be controlled with safe, natural techniques. Drinking fluids, cold compresses, and waste elimination with enemas all help to reduce the fever if it goes beyond the 104°F / 40°C mark . But most of the time the body regulates the fever by itself through sweating.
Whole body hyperthermia treatment one of the most common sense treatments!
A carefully controlled hyperthermia treatment has NO toxic side effects what so ever while being extremely effective. To the contrary it’s by far the best detox treatment there is. It increases your white blood cell count like no chemical substance ever can and arms your white blood cells with a protein that allows them to attack cancer cells more effectively. In combination with oxygen it increases hydrogen peroxide in your blood and it supports perfusion of anti cancer remedies into cancer cells.
For over 100 years fever has been observed and documented as one of the main causes of so called miraculous recoveries. Patients who developed a fever recovered and their tumors reduced. When a swamp was drained out the outskirts of Rome, the malaria (associated with high fever) rate dramatically dropped. At the same time the cancer rate in this area went up proportionally. These are documented studies that show that fever is not only designed to kill bacteria and viruses but also cancer cells.
“If you ask a cancer patient when they last had fever, they usually cant remember.”
Dr. Rau, Paracelsius Clinic
DO IT YOURSELF FEVER is not for everybody and especially not for those who are in a progressed and weakened state without the support of an open-minded doctor. The stress to the system can be a bit much and you need to be careful. But if you are at an early stage and want to give yourself a super boost then this is a dream come true. Many athletes use this treatment in Germany as a kind of doping to increase all body functions and to strengthen their immunity.
FIND SOMEONE TO DO IT WITH
If you are supported by a good friend or family member, or you have a group of patients that support each other, then this is the ultimate solution to train your immune system slowly back into shape. Start slow, then increase each time a little bit and even if you do not achieve a fever in the first few runs, you still detoxify dramatically. This is especially a dream come true for those who have been to a clinic and know how a moderate hyperthermia works. For you it’s just like a walk in the park.
COMBINE WITH VITAMIN C
Many of the patients who use one of our first prototype domes have found a local GP to give them a 40 – 60 gram Vitamin C IV once a week before they go into the dome. This way they recreate the exact treatment they had in the clinic. Alternatively you can use BioEnergy C from Dr. Gordon in high dose to support the detox process. This is amazing for those who do not have a willing GP close by.
USE AS FAR INFRARED (FIR) SAUNA
We have this dome sauna at home and the family is using it as a normal sauna to assist us with our detox regime. The dome is very comfy and relaxing, so even my kids enjoy their sauna while watching a video. A sauna helps to relax your mind and body, soothes your muscles, cleanses your skin (to look beautiful), helps you to sleep better and flushes out toxins. For me the most important part is that it flushes out toxins. In my opinion no one can ignore anymore the onslaught of toxins we have to deal with everyday. The deep sweating of a Far-Infrared sauna helps to reduce the unwanted toxins we store in our body.
Carefully Controlled Hyperthermia Therapy
With whole-body hyperthemia treatment, it is important to regulate your body temperature. Keeping hydrated with water and the head cool will help your body regulate its temperature. A thermometer or a device such as the iCelsius is a good way to monitor your core body temperature during your hyperthemia therapy.
You will also need a tool to gauge your temperature. The more accurate the tool works the better. The best choice in our opinion is the iCelsius.
Fever, a nonspecific acute-phase response, has been associated with improved survival and shortened disease duration in infections, but the mechanisms of these beneficial responses are poorly understood. We previously reported that increasing core temperature of bacterial endotoxin (LPS)-challenged mice to the normal febrile range modified expression of tumor necrosis factor alpha (TNF-α), interleukin 1β (IL-1β), and IL-6, three cytokines critical to mounting an initial defense against microbial pathogens, but survival was not improved in the warmer animals. We speculated that our inability to show a survival benefit of optimized cytokine expression in the warmer animals reflected our use of LPS, a nonreplicating agonist, rather than an infection with viable pathogens. The objective of this study was to determine if increasing murine core temperature altered cytokine expression and improved survival in an experimental bacterial peritonitis model. We showed that housing mice at 35.5°C rather than 23°C increased core temperature from 36.5 to 37.5°C to 39.2 to 39.7°C, suppressed plasma TNF-α expression for the initial 48 h, delayed gamma interferon expression, improved survival, and reduced the bacterial load in mice infected with Klebsiella pneumoniae peritonitis. We showed that the reduced bacterial load was not caused by a direct effect on bacterial proliferation and probably reflected enhanced host defense. These data suggest that the increase in core temperature that occurs during bacterial infections is essential for optimal antimicrobial host defense.
The febrile response is one of the most common features of infection and inflammation. However, temperature is rarely a variable in experimental immunological investigations. To determine whether the thermal microenvironment has any immunoregulatory potential in an Ag-dependent response, we applied a mild fever-range whole body hyperthermia (FR-WBH) protocol to BALB/c mice experiencing the contact hypersensitivity (CHS) reaction. We observed that the timing of this FR-WBH treatment relative to the different phases of the CHS response was crucial to the outcome. FR-WBH treatment before sensitization with a 0.5% FITC solution resulted in a depressed CHS response. This appears to be due to direct effects of FR-WBH on epidermal Langerhans cell trafficking to the draining lymph nodes. In contrast, application of FR-WBH directly after application of the elicitation dose of FITC solution resulted in an enhanced reaction. This result correlates with increased homing of lymphocytes to the site of elicitation. Overall, these data have important implications regarding the role of thermal changes experienced during infection and the clinical use of FR-WBH relative to immunotherapeutic strategies.
Rudolf Oehler, Erich Pusch, Maria Zellner, Peter Dungel, Nicole Hergovics, Monika Homoncik, Maja Munk Eliasen, Marianne Brabec, and E.R., 2001. Cell type–specific variations in the induction of hsp70 in human leukocytes by feverlike whole body hyperthermia. Cell Stress & Chaperones, 6(4), pp.306–315.
Fever has been associated with shortened duration and improved survival in infectious disease. The mechanism of this beneficial response is still poorly understood. The heat-inducible 70-kDa heat shock protein (Hsp70) has been associated with protection of leukocytes against the cytotoxicity of inflammatory mediators and with improved survival of severe infections. This study characterizes the induction of Hsp70 by feverlike temperatures in human leukocytes in vitro and in vivo. Using flow cytometry, Hsp70 expression was determined in whole blood samples. This approach eliminated cell isolation procedures that would greatly affect the results. Heat treatment of whole blood in vitro for 2 hours at different temperatures revealed that Hsp70 expression depends on temperature and cell type; up to 41°C, Hsp70 increased only slightly in lymphocytes and polymorphonuclear leukocytes. However, in monocytes a strong induction was already seen at 39°C, and Hsp70 levels at 41°C were 10-fold higher than in the 37°C control. To be as close as possible to the physiological situation during fever, we immersed healthy volunteers in a hot water bath, inducing whole body hyperthermia (39°C), and measured leukocyte Hsp70 expression. Hsp70 was induced in all leukocytes with comparable but less pronounced cell type–specific variations as observed in vitro. Thus, a systemic increase of body temperature as triggered by fever stimulates Hsp70 expression in peripheral leukocytes, especially in monocytes. This fever-induced Hsp70 expression may protect monocytes when confronted with cytotoxic inflammatory mediators, thereby improving the course of the disease.
Page, R.L. et al., 1987. Whole-body hyperthermia. Rationale and potential use for cancer treatment. Journal of veterinary internal medicine / American College of Veterinary Internal Medicine, 1(3), pp.110–120. Available at: http://www.scopus.com/inward/record.url?eid=2-s2.0-0023380813&partnerID=tZOtx3y1.
Whole-body hyperthermia is the controlled elevation of systemic temperature for therapeutic purposes. Historically, this treatment has been used for symptomatic control of many diseases. Recently, the potential therapeutic benefit of whole-body hyperthermia in the management of neoplastic disease has been investigated vigorously. The rationale for improved tumor control is based on heat-induced enhancement of the antineoplastic effects of radiation and chemotherapy. Although the complex biologic interaction of heat and radiation has been studied for many years, chemotherapy combined with hyperthermia has been studied less thoroughly. Despite a lack of adequate long-term laboratory and clinical investigation, use of whole-body hyperthermia with chemotherapy and radiotherapy is a logical and potentially powerful therapeutic strategy for neoplasia. Relevant issues regarding the application of whole-body hyperthermia with more traditional modes of therapy are being studied in preliminary clinical trials involving dogs and humans. Identification of optimal timing and sequencing of adjunctive therapy, proper cytotoxic drug application, methods to further minimize toxicity, and heat-sensitive tumor types will lead to expanded clinical use of whole-body hyperthermia. The historical development, clinical rationale, and application of whole-body hyperthermia for the control of disseminated or refractory neoplasia in humans and dogs is reviewed.
There is a clear rationale for using hyperthermia in cancer treatment. Treatment at temperatures between 40 and 44 ° C is cytotoxic for cells in an environment with a low pO 2 and low pH, conditions that are found specifically within tumour tissue, due to insufficient blood perfusion. Under such con- ditions radiotherapy is less effective, and systemically applied cytotoxic agents will reach such areas in lower concentrations than in well perfused areas. Therefore, the addition of hyperthermia to radio- therapy or chemotherapy will result in at least an additive effect. Furthermore, the effects of both radio- therapy and many drugs are enhanced at an increased temperature. Hyperthermia can be applied by several methods: local hyperthermia by external or internal energy sources, regional hyperthermia by perfusion of organs or limbs, or by irrigation of body cavities, and whole body hyperthermia. The use of hyperthermia alone has resulted in complete overall response rates of 13%. The clinical value of hyperthermia in addition to other treatment modalities has been shown in randomised trials. Significant improvement in clinical outcome has been demonstrated for tumours of the head and neck, breast, brain, bladder, cervix, rectum, lung, oesophagus, vulva and vagina, and also for melanoma. Additional hyperthermia resulted in remarkably higher (complete) response rates, accompanied by improved local tumour control rates, better palliative effects and/or better overall survival rates. Gener- ally, when combined with radiotherapy, no increase in radiation toxicity could be demonstrated. Whether toxicity from chemotherapy is enhanced depends on sequence of the two modalities, and on which tissues are heated. Toxicity from hyperthermia cannot always be avoided, but is usually of limited clinical relevance. Recent developments include improvements in heating techniques and thermometry, development of hyperthermia treatment planning models, studies on heat shock proteins and an effect on anti-cancer immune responses, drug targeting to tumours, bone marrow purging, combination with drugs targeting tumour vasculature, and the role of hyperthermia in gene therapy. The clinical results achieved to date have confirmed the expectations raised by results from experi- mental studies. These findings justify using hyperthermia as part of standard treatment in tumour sites for which its efficacy has been proven and, furthermore, to initiate new studies with other tumours. Hyperthermia is certainly a promising approach and deserves more attention than it has received until now.
Conceptual approaches of heat-induced cytotoxic effects against tumor cells must address factors affecting therapeutic index, i.e., the relative toxicity for neoplastic versus normal tissues. Accordingly, we investigated the effect of hyperthermia treatment (HT) on the induction of DNA fragmentation, apoptosis, cell-cycle distribution, NFkappaB mRNA expression, DNA-binding activity, and phosphorylation of IkappaBalpha in the normal human Mono Mac 6 (MM6) cells. For HT, cells were exposed to 43 degrees C. FACS analysis showed a 48.5% increase in apoptosis, increased S-phase fraction, and reduced G2 phase fraction after 43 degrees C treatments. EMSA analysis showed a dose-dependent inhibition of NFkappaB DNA-binding activity after HT. This HT-mediated inhibition of NFkappaB was persistent even after 48 h. Immunoblotting analysis revealed dose-dependent inhibition of IkappaBalpha phosphorylation. Similarly, RPA analysis showed that HT persistently inhibits NFkappaB mRNA. These results demonstrate that apoptosis upon HT exposure of MM6 cells is regulated by IkappaBalpha phosphorylation mediated suppression of NFkappaB.
Sauna therapy has been used for hundreds of years in the Scandinavian region as a standard health activity. Studies document the effectiveness of sauna therapy for persons with hypertension, congestive heart failure, and for post-myocardial infarction care. Some individuals with chronic obstructive pulmonary disease (COPD), chronic fatigue, chronic pain, or addictions also find benefit. Existing evidence supports the use of saunas as a component of depuration (purification or cleansing) protocols for environmentally-induced illness. While far-infrared saunas have been used in many cardiovascular studies, all studies applying sauna for depuration have utilized saunas with radiant heating units. Overall, regular sauna therapy (either radiant heat or far-infrared units) appears to be safe and offers multiple health benefits to regular users. One potential area of concern is sauna use in early pregnancy because of evidence suggesting that hyperthermia might be teratogenic. (Altern Med Rev 2011;16(3):215-225) Key words: sauna, thermal chamber, thermal stress, hyperthermia, infrared, far-infrared, congestive heart failure, CHF, myocardial infarction, MI, chronic heart failure, hypertension, weight loss, anorexia nervosa, depression, autoimmunity, fatigue, multiple chemical sensitivities, MCS, pesticides, polychlorinated biphenyls, PCBs, solvents, sweating, pregnancy, congenital defects, deputation, cleansing, detox, detoxification, purification Introduction Saunas have been utilized for hundreds or years, especially in the Scandinavian countries. Finland, with a population of five million, has close to one million saunas. Most Finns take a sauna bath weekly and grew up hearing the adage: “If the sauna, schnapps, and birch tar don’t help, then death is near.” (1) There are several distinct types of saunas: Finnish steam sauna (Finnish steam bath), dry-heat sauna, infrared saunas, and far-infrared (FIR) saunas. Radiant-heat Saunas (Finnish Steam Saunas and Dry-heat Saunas) When the term “sauna” is used in the medical literature without any modifiers (e.g., infrared), it generally refers to the Finnish steam sauna. This sauna uses a wood-paneled room with wooden benches and a radiant heater that keeps the temperature between 70 and 100[degrees]C (158-212[degrees]F) with a face level temperature of 80-90[degrees]C (176-194[degrees]F). Steam is produced by pouring water over heated rocks. Generally enough steam is produced to create a humidity of 50-60 g [H.sub.2]O vapor/[M.sup.3]. Standard length of a Finnish sauna is 5-20 minutes in the sauna, followed by cold immersion (swim or shower) and a period of room temperature recovery before repeating. In a single sauna session, this pattern is repeated 2-3 times. Dry-heat saunas are essentially the same as Finnish steam saunas; however, the room used is dry so steam is not produced. The procedure for these saunas is also roughly the same as that described for Finnish steam saunas. Infrared Saunas (Infrared and Far-infrared Saunas) Infrared saunas utilize a different heating element and typically do not achieve the same temperatures as the radiant heat saunas. There are also no hot rocks on which to splash water for humidity. There are two main types of infrared saunas–infrared and far-infrared (FIR). Infrared saunas use incandescent infrared heat lamps to produce heat. They emit primarily near-infrared wavelengths, with lesser amounts of middle-infrared, and perhaps a small amount…
OBJECTIVE This paper describes the successful treatment of two patients with chronic fatigue syndrome (CFS) using repeated thermal therapy. METHODS Two patients with CFS underwent treatment with prednisolone (PSL), with no satisfactory effect. They were subjected to thermal therapy that consisted of a far-infrared ray dry sauna at 60 degrees C and postsauna warming. The therapy was performed once a day, for a total of 35 sessions. After discharge, these subjects continued the therapy once or twice a week on an outpatient basis for 1 year. RESULTS Symptoms such as fatigue, pain, sleep disturbance, and low-grade fever were dramatically improved after 15 to 25 sessions of thermal therapy. Although PSL administration was discontinued, the subjects showed no relapse or exacerbation of symptoms during the first year after discharge. The patients became socially rehabilitated 6 months after discharge. CONCLUSIONS These results suggest that repeated thermal therapy might be a promising method for the treatment of CFS.
Vascular access malfunction, usually presenting with an inadequate access flow (Qa), is the leading cause of morbidity and hospitalization in hemodialysis (HD) patients. Many methods of thermal therapy have been tried for improving Qa but with limited effects. This randomized trial was designed to evaluate the effect of far-infrared (FIR) therapy on access flow and patency of the native arteriovenous fistula (AVF). A total of 145 HD patients were enrolled with 73 in the control group and 72 in the FIR group. A WS TY101 FIR emitter was used for 40 min, and hemodynamic parameters were measured by the Transonic HD(02) monitor during HD. The Qa(1)/Qa(2) and Qa(3)/Qa(4) were defined as the Qa measured at the beginning/at 40 min later in the HD session before the initiation and at the end of the study, respectively. The incremental change of Qa in the single HD session with FIR therapy was significantly higher than that without FIR therapy (13.2 +/- 114.7 versus -33.4 +/- 132.3 ml/min; P = 0.021). In comparison with control subjects, patients who received FIR therapy for 1 yr had (1) a lower incidence (12.5 versus 30.1%; P < 0.01) and relative incidence (one episode per 67.7 versus one episode per 26.7 patient-months; P = 0.03) of AVF malfunction; (2) higher values of the following parameters, including Delta(Qa(4) – Qa(3)) (36.2 +/- 82.4 versus -12.7 +/- 153.6 ml/min; P = 0.027), Delta(Qa(3) – Qa(1)) (36.3 +/- 166.2 versus -51.7 +/- 283.1 ml/min; P = 0.035), Delta(Qa(4) – Qa(2)) (99.2 +/- 144.4 versus -47.5 +/- 244.5 ml/min; P < 0.001), and Delta(Qa(4) – Qa(2)) – Delta(Qa(3) – Qa(1)) (62.9 +/- 111.6 versus 4.1 +/- 184.5 ml/min; P = 0.032); and (3) a better unassisted patency of AVF (85.9 versus 67.6%; P < 0.01). In conclusion, FIR therapy, a noninvasive and convenient therapeutic modality, can improve Qa and survival of the AVF in HD patients through both its thermal and its nonthermal effects.
To study the effects of infrared (IR) Sauna, a form of total-body hyperthermia in patients with rheumatoid arthritis (RA)\nand ankylosing spondylitis (AS) patients were treated for a 4-week period with a series of eight IR treatments. Seventeen\nRA patients and 17 AS patients were studied. IR was well tolerated, and no adverse effects were reported, no exacerbation\nof disease. Pain and stiffness decreased clinically, and improvements were statistically significant (p < 0.05 and p < 0.001 in RA and AS patients, respectively) during an IR session. Fatigue also decreased. Both RA and AS patients felt comfortable\non average during and especially after treatment. In the RA and AS patients, pain, stiffness, and fatigue also showed clinical\nimprovements during the 4-week treatment period, but these did not reach statistical significance. No relevant changes in\ndisease activity scores were found, indicating no exacerbation of disease activity. In conclusion, infrared treatment has\nstatistically significant short-term beneficial effects and clinically relevant period effects during treatment in RA and\nAS patients without enhancing disease activity. IR has good tolerability and no adverse effects.
We have previously reported that repeated 60°C sauna treatment improves hemodynamic data and clinical symptoms in patients with CHF. We hypothesized that the sauna restores endothelial function and then improves cardiac function. METHODS Twenty patients (62 ? 15 years) in New York Heart Association (NYHA) functional class II or III CHF were treated in a dry sauna at 60°C for 15 min and then kept on bed rest with a blanket for 30 min, daily for two weeks. Ten patients with CHF, matched for age, gender and NYHA functional class, were placed on a bed in a temperature-controlled (24°C) room for 45 min as the nontreated group. Using high-resolution ultrasound, we measured the diameter of the brachial artery at rest and during reactive hyperemia (percent flow-mediated dilation, %FMD: endothelium-dependent dilation), as well as after sublingual administration of nitroglycerin (%NTG: endothelium-independent dilation). Cardiac function was evaluated by measuring the concentrations of plasma brain natriuretic peptide (BNP). RESULTS Clinical symptoms were improved in 17 of 20 patients after two weeks of sauna therapy. The %FMD after two-week sauna treatment significantly increased from the baseline value, whereas the %NTG-induced dilation did not. Concentrations of BNP after the two-week sauna treatment decreased significantly. In addition, there was a significant correlation between the change in %FMD and the percent improvement in BNP concentrations in the sauna-treated group. In contrast, none of the variables changed at the two-week interval in the nontreated group. CONCLUSIONS Repeated sauna treatment improves vascular endothelial function, resulting in an improve- ment in cardiac function and clinical symptoms.